Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPICS-III saroglitazar magnesium in primary biliary cholangitis
2024-518718-14-00Phase 3Completed
- Sponsor
- Zydus Therapeutics
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Saroglitazar magnesium with Placebo (2 arms). Primary endpoint: Biochemical response at Week 52. Started Dec 2024; status: completed.
02
Drugs
saroglitazar magnesium
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-518718-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518718-14-00.